Separate market reports project growth in chronic kidney disease treatment and peritoneal dialysis, driven by diabetes, hypertension, aging populations, home-based care adoption and digital renal technologies.
BCC Research projects the global chronic kidney disease market will grow from $40.8 billion in 2022 to $131.4 billion by 2030, with a 9.3% CAGR for 2025-2030, while a separate report from The Insight Partners forecasts the peritoneal dialysis segment will expand from $11.56 billion in 2025 to $21.55 billion by 2034 at a 7.4% CAGR over 2026-2034. Both reports cite rising disease burden linked to diabetes, hypertension and aging populations, with North America leading because of advanced renal care infrastructure and reimbursement support. The peritoneal dialysis study highlights home-based care, automated peritoneal dialysis and remote monitoring as key growth areas, while both reports point to digital platforms and next-generation technologies as important innovation themes. Major companies cited across the reports include Fresenius Medical Care, DaVita, Baxter-related kidney care operations now under Vantive, Amgen, Pfizer and Novartis, alongside other renal care and digital health players.